Table 3.

Diagnostic performance of CESM enhancements and the corresponding histological result (benign vs. any malignancy) as the gold standard.

Enhancements	SE [95% CI]	SP [95% CI]	PPV [95% CI]	NPV [95% CI]	DA [95% CI]
Intensity	196/249 = 78.7% [73.6–83.8%]	116/128 = 90.6% [85.6–95.7%]	196/208 = 94.2% [91.1–97.4%]	116/169 = 68.6% [61.6–75.6%]	312/377 = 82.8% [79.0–86.6%]
Margin morphology	220/249 = 88.4% [84.4–92.3%]	115/128 = 89.8% [84.6–95.1%]	220/233 = 94.4% [91.5–97.4%]	115/144 = 79.9% [73.3–86.4%]	335/377 = 88.9% [85.7–92.0%]
Pattern	207/249 = 83.1% [78.5–87.8%]	121/128 = 94.5% [90.6–98.5%]	207/214 = 96.7% [94.4–99.1%]	121/163 = 74.2% [67.5–81.0%]	328/377 = 87.0% [83.6–90.4%]
Ground glass	203/249 = 81.5% [76.7–86.4%]	117/128 = 91.4% [86.6–96.3%]	203/214 = 94.9% [91.9–97.8%]	117/163 = 71.8% [64.9–78.7%]	320/377 = 84.9% [81.3–88.5%]
Enhancement score ≥ 2	230/249 = 92.4% [89.1–95.7%]	115/128 = 89.8% [84.6–95.1%]	230/243 = 94.7% [91.8–97.5%]	115/134 = 85.8% [79.9–91.7%]	345/377 = 91.5% [88.7–94.3%]

SE: sensitivity; SP: specificity; PPV: positive predictive value; NPV: negative predictive value; DA: diagnostic accuracy.